March 27th 2024
For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.
Dapagliflozin Misses Early Mark in COVID-19, but Kosiborod Sees Reasons for More Study
May 16th 2021The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective for multiple chronic conditions, might be similarly useful in an acute setting.
Read More
Off-the-Shelf Antiviral T Cells Can Treat Painful Complication After Stem Cell Transplants
May 8th 2021BK virus–specific T cells from healthy donors were an effective and safe off-the-shelf treatment for patients with leukemia or lymphoma who developed a painful and common complication after allogeneic hematopoietic stem cell transplantation.
Read More
A Complex Web of Factors Causes Climate Change to Increase the Risk and Burden of Skin Cancer
April 26th 2021Skin cancer is one of the most common diseases dermatologists deal with on a daily basis, and as global rates increase, it is clear that climate change is a contributory factor, said Eva R. Parker, MD, FAAD, assistant professor of dermatology, Vanderbilt University Medical Center, during her session at the American Academy of Dermatology Virtual Meeting Experience.
Read More
Regardless of Previous Medications, Baseline Characteristics, Ruxolitinib Cream Is Effective in AD
April 24th 2021Posters presented at the American Academy of Dermatology Virtual Meeting Experience show ruxolitinib cream was effective at treating atopic dermatitis (AD) regardless of previous treatments and in patients with more severe disease.
Read More
SGLT2 Inhibitors Changed the Treatment Paradigm for T2D, Have Implications for Managed Care
April 23rd 2021While the introduction of sodium glucose co-transporter 2 (SGLT2) inhibitors has benefitted patients with type 2 diabetes and impacted guidelines globally, these expensive therapies have managed care implications, explained Richard E. Pratley, MD, of AdventHealth Diabetes Institute and Johns Hopkins University School of Medicine.
Read More
Better Understanding of Potential Genetic Mutations May Lead to Improved PAH Diagnosis, Treatment
April 13th 2021A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.
Read More
Researchers Identify Patients With COPD at Risk for Hypercapnia Development
March 13th 2021Researchers analyzed 2 cohorts of patients with chronic obstructive pulmonary disease (COPD) to characterize who is most at risk for developing hypercapnia and who could most benefit from at-home noninvasive inhalation therapy.
Read More
Genetic Picture Emerges of Polycystic Kidney Disease in Ireland
February 27th 2021Cutting-edge genetic tools diagnosed 83% of Irish patients with polycystic kidney disease (PKD), identified 36 novel variants, and discovered that seemingly unrelated individuals with the same variant likely inherited it from a common ancestor.
Read More
Older Adults Are Often Excluded From RCTs of Systemic Treatments for Atopic Dermatitis
December 17th 2020Older adults are often at greater risk for adverse events from treatments, but they can also be excluded from randomized controlled trials (RCTs), making it difficult to know if findings are generalizable to this population.
Read More
Researchers Develop AI Model to Predict ICI Response in Advanced Melanoma
November 20th 2020Results of the artificial intelligence (AI) model were consistent no matter which immune checkpoint inhibitor (ICI) therapy patients received, suggesting that some biomarkers are not necessarily specific to the checkpoint target.
Read More
Risk of Death Differs for Elderly Patients With PAH Taking Endothelin Receptor Antagonists
November 20th 2020The mortality risk differs for the 3 endothelin receptor antagonists approved to treat pulmonary arterial hypertension (PAH) in elderly patients; however, a direct comparison in a controlled trial is still needed to confirm results.
Read More